Glenn Saldanha MD & CEO, Glenmark Pharmaceuticals “Plan for the bad when the going is good”

“Plan for the bad when the going is good” When I failed: Between 2000 and 2008, our revenue grew from $40 million to $450 million. We also concluded several out-licensing deals of our novel molecules. But 2008 was different. We were hit by a storm we didn’t anticipate. The recession impacted sales and receivables across the globe. Alongside, our out-licensed molecules did not meet their primary end point in human trials. Moreover, our fixed costs remained high because we had invested in infrastructure across countries . Our growth plans had hit a major roadblock. What I learnt: Uncertainty is a Read More


ˆ Back To Top